By / June 5, 2020

The United Kingdom and Brazil as the next markets for Khiron Life

The Canadian firm Khiron Life Sciences Corp. announced the first medical cannabis prescriptions in the United Kingdom and Brazil, through its participation in the Twenty21 research project, the largest medical cannabis study in Europe.

Currently, Project Twenty21 is sampling 20,000 patients in the United Kingdom, with whom it hopes to test the tolerability and effectiveness of medical cannabis as a therapeutic alternative to certain diseases.

If you want to know more about cannabis, how Khiron Life Sciences Corp. is expanding its cannabis business across different countries where cannabis is allowed, and to find out the latest cannabis news, download the mobile application.

Khiron Life partnership with the United Kingdom will help in the development of a new study

“Thanks to Khiron Life Sciences Corp., and the shared vision we have, we are accelerating the access to this therapeutic alternative for all those patients who need it,” said David Nutt, project leader and member of Drug Science, the United Kingdom’s independent scientific body linked to the cannabis study.

Khiron Life Sciences Corp. has partnered with this cannabis initiative to become the only Latin American supplier of medical cannabis-based pharmaceutical products from 2019. In addition, with this initiative, the company is expanding its business to European markets, which have the potential to become key cannabis hubs in the near future.

The medical cannabis study is carried out in conjunction with entities such as The Royal College of Psychiatrists, The British Pain Society, and the United Patients Alliance, and focuses on pathologies such as epilepsy, chronic pain, multiple sclerosis, and post-traumatic stress disorder.

For his part, Alvaro Torres, co-founder and CEO of Khiron Life Sciences Corp. said that “the first medical cannabis prescriptions that will be given to selected patients in the United Kingdom reflect” his “commitment to developing safe, responsible medicines of the highest standards that improve people’s quality of life.”

“We are confident that this milestone sets an important benchmark for the industry,” he said, solidifying his commitment to this partnership.

Medlive and Khiron Life, a partnership that will facilitate the cannabis business in Brazil

In February of this year, Khiron Life Sciences Corp. was authorized by Brazil’s National Health Surveillance Agency (Anvisa) to import its medical cannabis products for the modality of compassionate use by patients. That will allow the medical cannabis-based pharmaceutical product to be brought to Brazilian territory.

In addition, to facilitate access to patients who require it, the Canadian company signed an exclusivity agreement with Medlive, a company that distributes pharmaceutical products to more than 3,000 clinics, hospitals and pharmacies in southern Brazil.

In this way, the two companies will train an extensive network of doctors belonging to the centers with which they have an agreement on health education and the different pharmaceutical products that the company has developed.

This move will potentially help to expand the knowledge about cannabis-based products in these medical centers, and also help to destigmatize the use of cannabis.

Thus, they hope to put this product on sale and distribution in Brazilian territory by the third quarter of 2020. That would help hundreds, if not thousands, of patients in the Latin American giant to access new and modern alternative treatments.


(Featured image by Adam Derewecki via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Dinero, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.